Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 3Other hematologic neoplasm 2Myeloid 2Lymphoid 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Lymphoma, T-Cell, Peripheral 13Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Recurrence 10Leukemia 10Hodgkin Disease 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 7Lymphoma, Follicular 7Hematologic Neoplasms 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Biphenotypic, Acute 6Lymphoma, Extranodal NK-T-Cell 5Leukemia, Myelomonocytic, Chronic 5Primary Myelofibrosis 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Immunoblastic Lymphadenopathy 4Prostatic Neoplasms 3Neoplasms, Plasma Cell 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

pembrolizumab 5Gemcitabine 5Albumin-Bound Paclitaxel 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Bevacizumab 4venetoclax 3spartalizumab 3abemaciclib 3Sirolimus 3Pemetrexed 3Paclitaxel 3Leucovorin 3Ipilimumab 3Fluorouracil 3Doxorubicin 3Cisplatin 3Bortezomib 3130-nm albumin-bound paclitaxel 3manganese chloride 2fludarabine phosphate 2fludarabine 2copanlisib 2Taxes 2Midazolam 2Irinotecan 2Interleukin-2 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Azacitidine × Lymphoid × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡